Sickle cell cure will be cost-effective if health disparities considered -study finds

Multimillion-dollar gene therapies being tested for sickle cell disease will be cost-effective in the United States if health disparities tied in part to decreased access to healthcare are taken into account, researchers said at a meeting of blood-disease specialists. In the United States, about one of every 365 Black babies is born with sickle cell disease – a genetic disorder in which misshapen blood cells cause strokes, organ damage, severe pain and early death – according to the U.S. Centers for Disease Control and Prevention (CDC).

Go and Vote: Issued in Public Interest